Version 2.5.2.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 1R03MH084117-01
Project Title: Screen for RAS-Selective Lethal Compounds and VDAC Ligands
PI Information:NameEmailTitle
STOCKWELL, BRENT R. bs2198@columbia.edu WHITEHEAD FELLOW

Abstract: DESCRIPTION (provided by applicant): We are searching for compounds and mechanisms that cause oncogene-selective lethality. Such compounds eliminate tumor cells harboring specific oncogenic mutations, but have minimal effects on normal cells lacking these mutations. In this project, we propose to screen for new compounds that are selectively lethal to tumor cells expressing the RAS oncogenes. It is important to note that these compounds do not directly inhibit RAS proteins or the RAS pathway, but rather cause cell death specifically in tumor cells containing oncogenic RAS proteins. Using high-throughput screening of 70,000 compounds in isogenic, engineered tumor cell lines, we discovered three compounds selectively lethal to oncogenic-RAS-expressing cells. With the tools of synthetic chemistry, molecular biology and proteomics, we discovered that voltage dependent anion channels (VDACs) are target proteins for two of these compounds. We found that these compounds act through mitochondrial VDAC proteins to cause an oxidative, non-apoptotic death. These compounds thus revealed that oncogenic RAS signaling causes increased VDAC levels and that VDACs are novel gain-of-function targets for cancer therapeutics. Our results suggest that VDAC ligands are potential chemotherapeutic agents for the treatment of cancers with activated RAS signaling. We propose to find new RAS-selective lethal compounds and determine whether they act through VDAC proteins or through new mechanisms. New VDAC ligands would be valuable in trying to translate these compounds into potential therapeutics.

Public Health Relevance: Our goal is to define a new mechanism for selectively killing tumor cells containing oncogenic RAS, especially using VDAC modulators. Such small molecules may eventually provide new therapeutic agents for neoplastic diseases.

Thesaurus Terms:

There are no thesaurus terms on file for this project.

Institution: COLUMBIA UNIV NEW YORK MORNINGSIDE
Research Administration
NEW YORK, NY 100277003
Fiscal Year: 2008
Department: BIOLOGICAL SCIENCES
Project Start: 01-JUN-2008
Project End: 31-MAY-2009
ICD: NATIONAL INSTITUTE OF MENTAL HEALTH
IRG: ZMH1


CRISP Homepage Help for CRISP Email Us